Genzyme, a Sanofi company, is investing $80 million to build a new downstream processing facility for Fabrazyme (agalsidase beta), significantly expanding purification capacity to support anticipated growth in demand. The new plant will be adjacent to the new Fabrazyme cell culture manufacturing site in Framingham, MA.   Downstream processing involves the purification of material harvested from the cell culture manufacturing process. The final product is an intravenous (IV) infusion, which is fo...